Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Discovery & Translation

Expanding the base editor toolkit; plus new antibody discovery platforms and more

BioCentury’s roundup of translational news

February 8, 2023 10:07 PM UTC

A pair of Nature Communications studies from Tian-Lin Cheng’s lab at Fudan University describe a set of base editors engineered to have both A- and C-editing activity, and another set that was miniaturized and optimized for precision and potency. Both approaches involved engineering tRNA-specific adenosine deaminase (TadA), a bacterial-derived enzyme that forms the basis for adenine base editors.

The first study described 25 TadA orthologs engineered to generate functional Cas9-based adenine base editors (ABEs), cytosine base editors (CBEs) and fusion adenine–cytosine base editors (ACBEs); the latter offer greater flexibility than previously available A- or C-restricted deaminases. Five of the orthologs with improved editing efficiency and lowered DNA- and RNA-off-target effects and genotoxicity were selected for further development. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article